Neratinib information

Neratinib
Clinical data
Trade names	Nerlynx, Hernix
Other names	HKI-272
AHFS/Drugs.com	Monograph
MedlinePlus	a617034
License data	EU EMA: by INN; US DailyMed: Neratinib; US FDA: Nerlynx;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
Drug class	Antineoplastic agent
ATC code	L01EH02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name (2E)-N-[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide;
CAS Number	698387-09-6 ;
PubChem CID	9915743;
IUPHAR/BPS	5686;
DrugBank	DB11828 ;
ChemSpider	8091392 ;
UNII	JJH94R3PWB;
KEGG	D08950 ; as salt: D10898 ;
ChEMBL	ChEMBL180022 ;
CompTox Dashboard (EPA)	DTXSID70220132 ;
ECHA InfoCard	100.241.512
Chemical and physical data
Formula	C30H29ClN6O3
Molar mass	557.05 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)C=CCN(C)C;
	InChI InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+ ; Key:JWNPDZNEKVCWMY-VQHVLOKHSA-N ;
	(what is this?) (verify)

Neratinib (INN), sold under the brand name Nerlynx, is a tyrosine kinase inhibitor anti-cancer medication used for the treatment of breast cancer.^[3]^[4]

The most common side effect is diarrhea, which affects nearly all patients.^[4] Other common side effects include nausea (feeling sick), vomiting, tiredness, belly pain, rash, decreased appetite, stomatitis (sore, inflamed mouth), and muscle spasms.^[4]

^ "Summary Basis of Decision (SBD) for Nerlynx". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^ "Nerlynx 40 mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 13 November 2020.
^ ^a ^b Cite error: The named reference Nerlynx FDA label was invoked but never defined (see the help page).
^ ^a ^b ^c ^d Cite error: The named reference Nerlynx EPAR was invoked but never defined (see the help page).

[1] "Summary Basis of Decision (SBD) for Nerlynx". Health Canada. 23 October 2014. Retrieved 29 May 2022.

[2] "Nerlynx 40 mg Film-coated Tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 13 November 2020.

[Nerlynx_FDA_label-3] Cite error: The named reference Nerlynx FDA label was invoked but never defined (see the help page).

[Nerlynx_EPAR-4] Cite error: The named reference Nerlynx EPAR was invoked but never defined (see the help page).

Neratinib information

and 26 Related for: Neratinib information

Neratinib

Puma Biotechnology

Beacon Pharmaceuticals

Erythropoietin

Insulin

Afatinib

Lorlatinib

HER2

Epidermal growth factor

Targeted covalent inhibitors

Sorafenib

Gefitinib

Repotrectinib

Bevacizumab

Neurotrophic factors

Amitriptyline

Cerebrolysin

Trastuzumab deruxtecan

Neurotrophin

Faricimab

Vemurafenib

Vascular endothelial growth factor

Adult neurogenesis

Tyrosine kinase inhibitor

Fibroblast growth factor 23

Dabrafenib